Call for proposals: Evaluate Canadian Biotechnologies with Randomized Controlled Trials
15 May 2023
The Accelerating Clinical Trials/Accélérer les Essais Cliniques (ACT/AEC) Consortium has released a call for proposals entitled Evaluate Canadian Biotechnologies with Randomized Controlled Trials. Submit the full application to firstname.lastname@example.org by noon EST on July 7, 2023.
Given that most biotechnologies require randomized controlled trials (RCT) demonstrating efficacy and safety to obtain regulatory approvals, the objective of this request for applications (RFA) is to fund trials evaluating products from Canadian-controlled biotechnology companies in partnership with ACT Network clinical trialists. Through this RFA, ACT aims to provide foundational support to Canada’s Biomanufacturing and Life Sciences Strategy (BLSS) by enabling Canada’s best researchers and companies to undertake the clinical trials efficiently, aligned with BLSS, Pillar 3: Growing Businesses by Doubling Down on Existing and Emerging Areas of Strength; the goal being to improve the health of Canadians.
The nominated principal investigator(s) must be a Canadian researcher who affiliated with one of ACT’s 28 Networks and leadership must be in partnership with a biotech company representative.
Download the application information and instruction:
About Accelerating Clinical Trials/Accélérer les Essais Cliniques Consortium
The ACT/AEC Canada Consortium is made up of clinical trial units, research networks, provincial organizations, government and Canadian biotechnology organizations. The consortium’s work will bring many long-lasting benefits for the clinical trials community, which will ultimately improve the health of Canadians.
Clinical Trials BC is a collaborator with the consortium. We support clinical trial investigators, sites and institutions to ensure a world-class destination for clinical trials. Focusing on infrastructure and capacity building with a collaborative approach, we enable clinical trial excellence across British Columbia.